Carborane derivatives as inhibitors of human carbonic anhydrase isoenzymes

Human carbonic anhydrases (CAs) play important roles in many pathological processes and several CA isoenzymes thus represent diagnostic and therapeutic targets. The development of certain isoform-specific sulfonamide inhibitor is still an important task in current medicine.
Technology description: 
We have developed unique selective CAIX inhibitors with anticancer properties based on carborane scaffold to structure-assisted design of novel and original inhibitors targeting therapeutically relevant isoenzymes of human carbonic anhydrase.
Development status: 
Laboratory scale, data on cell lines, crystal structure, limited ADME/Tox data, in vivo pharmacology and pharmacodynamics.
Novelty, in brief, is represented by the intended elaboration of carborane, heteroborane and metallaborane compounds as active-site inhibitors of CA isoenzymes. All currently used inhibitors anhydrase inhibitors contain a sulfonamide or a sulfamate moiety connected to so called ‘ring structure’ which is usually a 5- or 6-membered aromatic ring or conjugated ring system containing nitrogen, oxygen, and/or sulfur heteroatoms. The ‘ring structure’ bears characteristics or functionality which modulates the affinity toward certain CA isoform. The use of three-dimensional boron cluster is a novel approach in development of isoform-specific CA inhibitors. Selected sulfamides incorporating cluster with inhibitory effects toward CAs (IC50 values in low micromolar and submicromolar range, some of the inhibitors being more than 50-times more selective toward the tumor specific CAIX than for CAII abundantly present in normal tissues).
Commercial offer: 
Exclusive/non-exclusive licence to the patents, related know-how and data.
IP protection: 
EP 2 771 015 US 9,290,529
Technology/IP owners: 
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague Institute of Molecular Genetics, Czech Academy of Sciences, Prague Institute of Inorganic Chemistry, Czech Academy of Sciences, Prague Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc
More information is available upon signing a CDA/NDA. Please contact IMTM´s director ( or the technology transfer office (